Aytu BioPharma Q4 Revenue Rises 6.4% as EXXUA Launch Gains Traction
AYTU sits 37% above its 52-week low of $1.65 on elevated volume (7.4× avg).
Summary
Aytu BioPharma reported Q4 FY2026 revenue of $16.1M, up 6.4% YoY, with EXXUA contributing $3.9M in its first full quarter. Net loss narrowed to near break-even from $19.8M a year ago.
Key Events · Earnings and Guidance · AYTU
-
Q4 Revenue Up 6.4% to $16.1M
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter, driven by EXXUA launch momentum.
-
EXXUA Launch Accelerates
EXXUA generated $3.9 million in Q4 net revenue with 3,323 total prescriptions, up approximately 138% from 1,398 in Q3 FY2026. Monthly prescriptions reached a record 1,261 in June.
-
Net Loss Narrows to Near Break-Even
Q4 net loss was approximately break-even at less than ($0.1) million, compared to a net loss of ($19.8) million in Q4 FY2025, which included $18.1 million of combined impairment expense and derivative warrant liabilities loss.
-
Cash Position of $26.3M
Cash and cash equivalents were $26.3 million at June 30, 2026, compared to $31.0 million at June 30, 2025, providing runway for continued EXXUA commercialization investments.
Analysis · AYTU · Life Sciences
Aytu BioPharma reported Q4 FY2026 net revenue of $16.1 million, up 6.4% year-over-year, driven by the first full quarter of EXXUA commercialization. EXXUA generated $3.9 million in revenue with 3,323 prescriptions, up 138% sequentially, while the legacy ADHD portfolio declined to $10.4 million due to generic competition and commercial prioritization of EXXUA. Net loss narrowed dramatically to approximately break-even from a $19.8 million loss a year ago, helped by a $1.0 million derivative warrant liability gain. The company holds $26.3 million in cash, providing runway as it invests in the EXXUA launch. This is the first disclosure of these results and shows meaningful progress on the company's strategic pivot toward EXXUA, though full-year revenue still declined 13.3%.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AYTU was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.9M. The 52-week trading range was $1.65 to $3.07. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.